ICYMI: Cure Sickle Cell Disease by 2030?
IGT Scientific, Academic, and Medical Council Chair Dr. Donna Christian-Christensen recently wrote an opinion piece for Inside Sources,...
A Bold Goal to Cure Sickle Cell Disease by 2030
By IGT Scientific, Academic & Medical Advisory Council Chair Donna M. Christensen Last week, during the Congressional Black Caucus...
IGT Comments on CMS Fiscal Year 2023 Medicare Inpatient Prospective Payment Systems Proposed Rule
Earlier this month the Institute for Gene Therapies submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on...
New Resource: Understanding the Complexity of Gene Therapy Science & Manufacturing
Gene therapies present a unique opportunity to change the way we treat diseases. Given the complex nature of these transformative...
IGT Chairman Erik Paulsen Joins Healthy Future Task Force Treatments Subcommittee Roundtable
On April 28th, IGT Chairman Paulsen joined leaders in Congress on the Healthy Future Task Force Treatments Subcommittee Roundtable. The...
A Troubling Policy Proposal
Last week, IGT joined many organizations in expressing concern about a policy proposal that would restrict patients’ access to certain...
Prioritizing Minority Health
By IGT Scientific, Academic & Medical Advisory Council Chair Donna M. Christensen April is National Minority Health Month, an important...
IGT Statement on the Introduction of the Medicaid VBPs for Patients Act (H.R. 7389)
WASHINGTON, DC (April 5, 2022) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...
Rare Disease Day Spotlight: Hope for HPP Patients
By Deborah Fowler, President & Founder of Soft Bones Rare Disease Day is a critical awareness day for many patients and families who are...
Changing the Way We Look at Huntington’s Disease
By IGT Patient Advocacy Advisory Council Member and Huntington's Disease Patient Advocate Seth Rotberg As we enter the third year of the...